The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFNγ
Open accessPublished version of a preprint
Abstract
B-RafV600E inhibitors have been suggested to promote tumor regression with the help of host immunity, but this hypothesis has not been examined directly in detail. In this study, we profiled immunologic changes in the tumor microenvironment and tumor-infiltrating lymphocytes (TIL) in a B-RafV600E/Pten-driven murine model of melanoma after administration of the B-RafV600E small molecule inhibitor PLX4720. In this model, we found that as tumors developed, they gradually acquired immunosuppressive features, including accumulation of regulatory T cells (Treg) and CD11b+/Gr-1+ myeloid cells and loss of Th1 effector functions on CD4+ TILs, such as CD40L and IFNγ expression. PLX4720 administration promoted development of a more immune stimulatory microenvironment associated with a relative increase in CD40L and IFNγ expression on intratumoral CD4+ TILs and a reduced accumulation of Tregs and CD11b+/Gr-1+ myeloid cells. Strikingly, CD40L or IFNγ blockade compromised the ability of PLX4720 to inhibit melanoma growth. Supporting this result, agonistic CD40 antibody was sufficient to evoke antitumor immunity and suppress tumor growth in tumor-bearing mice. Taken together, our results establish the critical role of immune-related changes, with key contributions for CD40L and IFNγ signaling in the antitumor responses triggered in vivo by B-RafV600E inhibitors. Cancer Res; 74(12); 3205–17. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We used a subcutaneously engrafted BRAFV600E melanoma model, which is clinically relevant and ICI-resistant23,24.”
From Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy (2025) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T. J., Mok, S., Cass, A. A., Haynes, N. M., Kinross, K. M., Yagita∥, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 274
RetractedExploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144
Protective and pathogenic functions of macrophage subsets
Murray, P. J., & Wynn, T. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri3073 · Cited by 5,269
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
Self-citationCD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,706
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.006 · Cited by 1,355
Self-citationMetabolic Regulation of T Lymphocytes
MacIver, N. J., Michalek, R. D., & Rathmell, J. C. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095956 · Cited by 1,244
Cited by
Sorted by citations
Items 101–125 of 125
Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma
Ziogas, D. C., Konstantinou, F., Bouros, S., & Gogas, H. J. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1711737 · Cited by 8
Helper Innate Lymphoid Cells—Unappreciated Players in Melanoma Therapy
Garofalo, C., Cerantonio, A., Muscoli, C., Mollace, V., Viglietto, G., Marco, C. D., & Cristiani, C. M. (2023) · Cancers · doi:10.3390/cancers15030933 · Cited by 6
Synergistic effects of low‑dose chemotherapy and T cells in renal cell carcinoma
Xu, D., Ding, M., Tong, P., Chong, Y., Gu, W., Li, Y., Fang, X., & Li, N. (2020) · Oncology Reports · doi:10.3892/or.2020.7679 · Cited by 6
Hao, X., Falo, L. D., Chen, G., Zhang, J., Carey, C. D., Storkus, W. J., Falo, L. D., & You, Z. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001179 · Cited by 6
Bari, S., Muzaffar, J., & Eroglu, Z. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221090306 · Cited by 6
Sanlorenzo, M., Vujic, I., Moy, A., Quaglino, P., Fierro, M. T., Gammaitoni, L., Carnevale‐Schianca, F., Aglietta, M., & Sangiolo, D. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1069272 · Cited by 6
Optimization of Culture Media for Ex vivo T-Cell Expansion for Adoptive T-Cell Therapy
Rahimmanesh, I., Tavangar, M., Zahedi, S. N., Azizi, Y., & Shahreza, H. K. (2022) · Advanced Biomedical Research · doi:10.4103/abr.abr_349_21 · Cited by 5
Morgese, F., Cognigni, V., Scortichini, L., Ranallo, N., Lunerti, V., Migliore, A., Tronconi, F., & Berardi, R. (2022) · Molecular and Clinical Oncology · doi:10.3892/mco.2022.2598 · Cited by 5
Ho, P., & Kaech, S. M. (2014) · OncoImmunology · doi:10.4161/onci.29126 · Cited by 5
Self-citationCAR-T triggers TAM reeducation and adaptive anti-tumor response via TREM2 deficiency or CD40 agonist
Liu, T., Gao, H., Xi, Z., Yu, T., Gu, Y., Mai, H., Yuan, H., Liu, Y., Liu, H., Zhang, Q., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102539 · Cited by 5
Sander, C., Rush, E. A., Shi, J. R., Arantes, L. M. R. B., Tesi, R. J., Ross, M. A., Calderon, M. J., Watkins, S. C., Kirkwood, J. M., Ferris, R. L., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03538-w · Cited by 4
Vella, L. J., Andrews, M. C., Behren, A., Cebon, J. S., & Woods, K. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.929943 · Cited by 2
BRAF Inhibitor Therapy-Related Encephalitis in a Patient with Metastatic Melanoma
Babacan, N. A., Peguero, E. N., Forsyth, P. A., & Eroglu, Z. (2021) · The Oncologist · doi:10.1002/onco.13896 · Cited by 2
Integrated approaches to sensitizing melanoma to radiotherapy
Aseeri, A. A., AlKhafaje, Z., Hussein, U. A.-R., Adel, Z., Alkadir, O. K. A., Aldulaimi, A., Saeed, S. M., Taher, W. M., Alwan, M., & Smerat, A. (2026) · Strahlentherapie und Onkologie · doi:10.1007/s00066-025-02501-0 · Cited by 1
Lin, K., GU, Q., & Lai, X. (2023) · Biocell · doi:10.32604/biocell.2023.043298 · Cited by 1
Winograd, R. (2015) · ScholarlyCommons (University of Pennsylvania)
Schäffer, A. A. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737383720.793571667
Winograd, R., Byrne, K. T., Evans, R. A., Odorizzi, P. M., Meyer, A. R. L., Bajor, D. L., Clendenin, C., Stanger, B. Z., Furth, E. E., Wherry, E. J., et al. (2023) · doi:10.1158/2326-6066.c.6548740.v1
Winograd, R., Byrne, K. T., Evans, R. A., Odorizzi, P. M., Meyer, A. R. L., Bajor, D. L., Clendenin, C., Stanger, B. Z., Furth, E. E., Wherry, E. J., et al. (2023) · doi:10.1158/2326-6066.22538320.v1
Effect of target therapy with BRAF and MEK inhibitors on the immune system in metastatic melanoma
Řandová, L., & Kodet, O. (2023) · Onkologie · doi:10.36290/xon.2023.022
Innate Immune Remodeling Drives Therapy Resistance via Macrophage–NK Cell CrosstalkPreprint
Hsu, C., Lee, K., Chen, J., Donahue, L. R., Lin, J., Kacaj, D., Zhang, Z., & White, A. C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.22.666055
Sander, C., Rush, E. A., Shi, J., Arantes, L. M. R. B., Tesi, R. J., Ross, M. A., Calderon, M. J., Watkins, S. C., Kirkwood, J. M., Ferris, R. L., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20374584
Chi, F., Liu, C.-B., Li, J., Xia, X.-W., Hua, Q.-J., & Wang, W. (2026) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v18.i5.118319
Hsu, C., Chen, J., Donahue, L. R., Lee, K., Chang, Y.-W., Lin, J., Kacaj, D., White, R. M., Weiss, R. S., Zhang, Z., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-5751
Nguyen, K., Quackenbush, M., Basbous, S., Rodriguez, H., Lattanzi, G., Quansah, E., Bowman, C. R., Novak, S. W., Boassa, D., Yu, J., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117957
Metadata
- Authors
- Ho, P.-C., Meeth, K. M., Tsui, Y.-C., Srivastava, B., Bosenberg, M. W., & Kaech, S. M.
- Affiliations
- Howard Hughes Medical Institute (US)
- Corresponding author
- Kaech, Susan M.
- Venue
- Cancer Research
- Published
- 2014-06-12
- Volume
- 74
- Issue
- 12
- Pages
- 3205-3217
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC4063281
- OpenAlex
- W1974056979
- Cited by
- 126
- References
- 53
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 4 · 2023: 16 · 2022: 15 · 2021: 15 · 2020: 19 · 2019: 10 · 2018: 4 · 2017: 7 · 2016: 9 · 2015: 12 · 2014: 5
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Yale University
- National Cancer Institute (P50CA121974, P30CA016359)
- National Institute of Allergy and Infectious Diseases (R01AI074699)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- BRAF V600E inhibitors, PLX4720, melanoma, tumor microenvironment, tumor-infiltrating lymphocytes, CD40 ligand, interferon-gamma, regulatory T cells, myeloid cells, antitumor immunity, immune checkpoint blockade, PTEN
- MeSH terms
- Animals, Antigen-Presenting Cells, Antineoplastic Agents, Drug Screening Assays, Antitumor, Indoles, Interferon-gamma, Macrophages, Melanoma, Experimental, Mice, Transgenic, Skin Neoplasms, Sulfonamides, Signal Transduction, CD4-Positive T-Lymphocytes, Mutation, Missense, CD40 Ligand, Proto-Oncogene Proteins B-raf, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
